Next Article in Journal
Transitioning from Acute to Chronic Pain: An Examination of Different Trajectories of Low-Back Pain
Next Article in Special Issue
A Health System’s Journey toward Better Population Health through Empanelment and Panel Management
Previous Article in Journal
Striking a Balance: A Qualitative Study of Next of Kin Participation in the Care of Older Persons in Nursing Homes in Sweden
Previous Article in Special Issue
The Geography of the Alzheimer’s Disease Mortality in Spain: Should We Focus on Industrial Pollutants Prevention?
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
Healthcare 2018, 6(2), 47; https://doi.org/10.3390/healthcare6020047

Modeling the Population Health Impact of Introducing a Modified Risk Tobacco Product into the U.S. Market

1
Philip Morris International R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, Neuchâtel 2000, Switzerland
2
P. N. Lee Statistics and Computing Ltd., 17 Cedar Road, Sutton SM2 5DA, UK
*
Author to whom correspondence should be addressed.
Received: 4 April 2018 / Revised: 24 April 2018 / Accepted: 26 April 2018 / Published: 16 May 2018
(This article belongs to the Special Issue Population Health Management)
Full-Text   |   PDF [2126 KB, uploaded 16 May 2018]   |  

Abstract

Philip Morris International (PMI) has developed the Population Health Impact Model (PHIM) to quantify, in the absence of epidemiological data, the effects of marketing a candidate modified risk tobacco product (cMRTP) on the public health of a whole population. Various simulations were performed to understand the harm reduction impact on the U.S. population over a 20-year period under various scenarios. The overall reduction in smoking attributable deaths (SAD) over the 20-year period was estimated as 934,947 if smoking completely went away and between 516,944 and 780,433 if cMRTP use completely replaces smoking. The reduction in SADs was estimated as 172,458 for the World Health Organization (WHO) 2025 Target and between 70,274 and 90,155 for the gradual cMRTP uptake. Combining the scenarios (WHO 2025 Target and cMRTP uptake), the reductions were between 256,453 and 268,796, depending on the cMRTP relative exposure. These results show how a cMRTP can reduce overall population harm additionally to existing tobacco control efforts. View Full-Text
Keywords: public; tobacco; risk; modified; reduced; nicotine; non-combustible; health; smoking; harm public; tobacco; risk; modified; reduced; nicotine; non-combustible; health; smoking; harm
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Djurdjevic, S.; Lee, P.N.; Weitkunat, R.; Sponsiello-Wang, Z.; Lüdicke, F.; Baker, G. Modeling the Population Health Impact of Introducing a Modified Risk Tobacco Product into the U.S. Market. Healthcare 2018, 6, 47.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Healthcare EISSN 2227-9032 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top